NUVATION
PharmaNUVATION is a pharmaceutical company focused on Oncology. Key products include IBTROZI.
FDA Novel Drug Designations
(2025)See 1 novel approval →
NUVATION at a Glance
- Fast trial execution (21 months median completion)
NUVATION's Key Drugs
NUVATION's core commercial portfolio centers on IBTROZI, spanning Oncology — its most strategically important drugs approved in the last 15 years.
NUVATION's Recent FDA Approvals
NUVATION secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
NUVATION's Therapeutic Areas
NUVATION's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NUVATION's Top Competitors
NUVATION's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NUVATION Pipeline Snapshot
NUVATION has 13 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 3 Phase 2 and 8 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • IBTROZI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/3 completed
- • Speed: 21 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-06-11
- Latest
- 2025-06-11
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges